Literature DB >> 28768908

Nonmyocyte ERK1/2 signaling contributes to load-induced cardiomyopathy in Marfan mice.

Rosanne Rouf1, Elena Gallo MacFarlane2, Eiki Takimoto1, Rahul Chaudhary1, Varun Nagpal2, Peter P Rainer1, Jay G Bindman2, Elizabeth E Gerber2, Djahida Bedja1, Christopher Schiefer1, Karen L Miller1, Guangshuo Zhu1, Loretha Myers2, Nuria Amat-Alarcon1, Dong I Lee1, Norimichi Koitabashi1, Daniel P Judge1, David A Kass1, Harry C Dietz2,3.   

Abstract

Among children with the most severe presentation of Marfan syndrome (MFS), an inherited disorder of connective tissue caused by a deficiency of extracellular fibrillin-1, heart failure is the leading cause of death. Here, we show that, while MFS mice (Fbn1C1039G/+ mice) typically have normal cardiac function, pressure overload (PO) induces an acute and severe dilated cardiomyopathy in association with fibrosis and myocyte enlargement. Failing MFS hearts show high expression of TGF-β ligands, with increased TGF-β signaling in both nonmyocytes and myocytes; pathologic ERK activation is restricted to the nonmyocyte compartment. Informatively, TGF-β, angiotensin II type 1 receptor (AT1R), or ERK antagonism (with neutralizing antibody, losartan, or MEK inhibitor, respectively) prevents load-induced cardiac decompensation in MFS mice, despite persistent PO. In situ analyses revealed an unanticipated axis of activation in nonmyocytes, with AT1R-dependent ERK activation driving TGF-β ligand expression that culminates in both autocrine and paracrine overdrive of TGF-β signaling. The full compensation seen in wild-type mice exposed to mild PO correlates with enhanced deposition of extracellular fibrillin-1. Taken together, these data suggest that fibrillin-1 contributes to cardiac reserve in the face of hemodynamic stress, critically implicate nonmyocytes in disease pathogenesis, and validate ERK as a therapeutic target in MFS-related cardiac decompensation.

Entities:  

Keywords:  Cardiology; Genetics

Year:  2017        PMID: 28768908      PMCID: PMC5543913          DOI: 10.1172/jci.insight.91588

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  56 in total

1.  Stretching cardiac myocytes stimulates protooncogene expression.

Authors:  I Komuro; T Kaida; Y Shibazaki; M Kurabayashi; Y Katoh; E Hoh; F Takaku; Y Yazaki
Journal:  J Biol Chem       Date:  1990-03-05       Impact factor: 5.157

2.  Palliative Mitral Valve Repair During Infancy for Neonatal Marfan Syndrome.

Authors:  Hiroto Kitahara; Ryo Aeba; Hidenobu Takaki; Hideyuki Shimizu
Journal:  Ann Thorac Surg       Date:  2016-05       Impact factor: 4.330

3.  Peptide growth factors can provoke "fetal" contractile protein gene expression in rat cardiac myocytes.

Authors:  T G Parker; S E Packer; M D Schneider
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

4.  Novel exon skipping mutation in the fibrillin-1 gene: two 'hot spots' for the neonatal Marfan syndrome.

Authors:  P Booms; J Cisler; K R Mathews; M Godfrey; F Tiecke; U C Kaufmann; U Vetter; C Hagemeier; P N Robinson
Journal:  Clin Genet       Date:  1999-02       Impact factor: 4.438

5.  Diagnosis and management of infantile marfan syndrome.

Authors:  R P Morse; S Rockenmacher; R E Pyeritz; S P Sanders; F R Bieber; A Lin; P MacLeod; B Hall; J M Graham
Journal:  Pediatrics       Date:  1990-12       Impact factor: 7.124

6.  Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK.

Authors:  S Eguchi; P J Dempsey; G D Frank; E D Motley; T Inagami
Journal:  J Biol Chem       Date:  2000-12-14       Impact factor: 5.157

Review 7.  TGF-beta1 and angiotensin networking in cardiac remodeling.

Authors:  Stephan Rosenkranz
Journal:  Cardiovasc Res       Date:  2004-08-15       Impact factor: 10.787

8.  Cardiac hypertrophy-induced changes in mRNA levels for TGF-beta 1, fibronectin, and collagen.

Authors:  F J Villarreal; W H Dillmann
Journal:  Am J Physiol       Date:  1992-06

9.  Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats.

Authors:  Fumitaka Kuwahara; Hisashi Kai; Keisuke Tokuda; Mamiko Kai; Akira Takeshita; Kensuke Egashira; Tsutomu Imaizumi
Journal:  Circulation       Date:  2002-07-02       Impact factor: 29.690

10.  Developmental expression of fibrillin genes suggests heterogeneity of extracellular microfibrils.

Authors:  H Zhang; W Hu; F Ramirez
Journal:  J Cell Biol       Date:  1995-05       Impact factor: 10.539

View more
  14 in total

Review 1.  Marfan syndrome.

Authors:  Dianna M Milewicz; Alan C Braverman; Julie De Backer; Shaine A Morris; Catherine Boileau; Irene H Maumenee; Guillaume Jondeau; Arturo Evangelista; Reed E Pyeritz
Journal:  Nat Rev Dis Primers       Date:  2021-09-02       Impact factor: 65.038

2.  Differential effects of angiotensin II type I receptor blockers on reducing intraocular pressure and TGFβ signaling in the mouse retina.

Authors:  Ralph J Hazlewood; Qingxia Chen; Frances K Clark; John Kuchtey; Rachel W Kuchtey
Journal:  PLoS One       Date:  2018-08-09       Impact factor: 3.240

Review 3.  Cardiac fibrosis: new insights into the pathogenesis.

Authors:  Zhen-Guo Ma; Yu-Pei Yuan; Hai-Ming Wu; Xin Zhang; Qi-Zhu Tang
Journal:  Int J Biol Sci       Date:  2018-09-07       Impact factor: 6.580

4.  An integrative systems approach identifies novel candidates in Marfan syndrome-related pathophysiology.

Authors:  Raghu Bhushan; Lukas Altinbas; Marten Jäger; Marcin Zaradzki; Daniel Lehmann; Bernd Timmermann; Nicholas P Clayton; Yunxiang Zhu; Klaus Kallenbach; Georgios Kararigas; Peter N Robinson
Journal:  J Cell Mol Med       Date:  2019-01-24       Impact factor: 5.310

Review 5.  TGF-β Signaling-Related Genes and Thoracic Aortic Aneurysms and Dissections.

Authors:  Norifumi Takeda; Hironori Hara; Takayuki Fujiwara; Tsubasa Kanaya; Sonoko Maemura; Issei Komuro
Journal:  Int J Mol Sci       Date:  2018-07-21       Impact factor: 5.923

6.  Heart failure and sudden cardiac death in heritable thoracic aortic disease caused by pathogenic variants in the SMAD3 gene.

Authors:  Julie De Backer; Alan C Braverman
Journal:  Mol Genet Genomic Med       Date:  2018-05-01       Impact factor: 2.183

7.  Localized Antileptin Therapy Prevents Aortic Root Dilatation and Preserves Left Ventricular Systolic Function in a Murine Model of Marfan Syndrome.

Authors:  Sudeshna Fisch; Noa Bachner-Hinenzon; Offir Ertracht; Liang Guo; Yhara Arad; Danny Ben-Zvi; Ronglih Liao; Jacob Schneiderman
Journal:  J Am Heart Assoc       Date:  2020-05-07       Impact factor: 5.501

8.  Spontaneous Right Ventricular Pseudoaneurysms and Increased Arrhythmogenicity in a Mouse Model of Marfan Syndrome.

Authors:  Felke Steijns; Marjolijn Renard; Marine Vanhomwegen; Petra Vermassen; Jana Desloovere; Robrecht Raedt; Lars E Larsen; Máté I Tóth; Julie De Backer; Patrick Sips
Journal:  Int J Mol Sci       Date:  2020-09-24       Impact factor: 5.923

9.  Myocardial disease and ventricular arrhythmia in Marfan syndrome: a prospective study.

Authors:  Laura Muiño-Mosquera; Hans De Wilde; Daniel Devos; Danilo Babin; Luc Jordaens; Anthony Demolder; Katya De Groote; Daniel De Wolf; Julie De Backer
Journal:  Orphanet J Rare Dis       Date:  2020-10-23       Impact factor: 4.123

10.  Effects of fibrillin mutations on the behavior of heart muscle cells in Marfan syndrome.

Authors:  Jeffrey Aalders; Laurens Léger; Louis Van der Meeren; Natasja Van den Vreken; Andre G Skirtach; Sanjay Sinha; Julie De Backer; Jolanda van Hengel
Journal:  Sci Rep       Date:  2020-10-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.